患者由来異種移植片/PDXモデル市場：タイプ、腫瘍タイプ、用途、エンドユーザー別-2025-2030年の世界予測

患者由来異種移植片/PDXモデル市場は、2023年に3億2,636万米ドルと評価され、2024年には3億6,524万米ドルに達すると予測され、CAGR 12.27％で成長し、2030年には7億3,407万米ドルに達すると予測されています。

患者由来異種移植（PDX）モデルは、がん研究において不可欠なツールであり、in vitro研究と臨床応用をつなぐ重要な架け橋となっています。このモデルでは、ヒト腫瘍組織を免疫不全マウスに移植することで、患者の腫瘍の遺伝的不均一性を維持しています。この忠実性により、PDXモデルは前臨床試験や個別化医療イニシアチブを加速する上で非常に貴重なものとなっています。PDXモデルの必要性は、治療効果のより正確な予測を提供する能力にあり、それによって医薬品開発を助け、従来の細胞株モデルの限界を克服します。PDXモデルは主に腫瘍学に応用され、抗がん剤のスクリーニングや生物製剤の開発をサポートしています。主なエンドユーザーは、研究機関、製薬会社、医薬品開発業務受託機関（CRO）などです。

PDXモデル市場は、がん罹患率の増加、がん治療薬の充実したパイプライン、精密医療の重視の高まりによって牽引されています。遺伝子編集やシーケンシングの技術的進歩も市場成長を大きく後押ししています。新たな開発機会としては、データ解析のための人工知能の統合や、腫瘍微小環境のシミュレーションを強化する3D PDXモデルの開発などが挙げられます。企業は、モデルの精度と予測可能性を高めるためにこれらの分野に投資することで、これらの機会を活用することができます。しかし、モデル開拓にかかる高コスト、動物使用に関する倫理的懸念、小規模バイオテクノロジー企業のアクセス制限などの課題が、市場成長の妨げになる可能性があります。

イノベーションを促進するためには、開発プロセスを最適化してコストを削減すること、希少がん種をカバーするためにモデルの多様性を高めること、PDXで得られた知見と患者の転帰との関連性を高めるために非臨床試験デザインを進歩させることに研究開発は焦点を当てるべきです。また、学術機関と産業界との連携を強化することで、イノベーションを促進することができます。PDXモデル市場は非常にダイナミックであり、継続的な技術進歩と、サービスポートフォリオや地理的範囲の拡大を目的とした戦略的提携や買収による競合情勢が特徴です。

市場力学：急速に進化する患者由来異種移植片/PDXモデル市場の主要市場インサイトを公開

患者由来異種移植片/PDXモデル市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 個別化医療に対する需要の高まり
  • オンコロジーと前臨床開発
  • 申請者の前臨床プログラムおよび文書作成のための政府プログラムによる資金援助とサービス
• 市場抑制要因
  • 個別化PDXモデルの高コスト
• 市場機会
  • ヒト化PDXモデルに対する需要の高まり
  • 製薬企業の研究開発における成長
• 市場の課題
  • がん研究における動物の倫理的使用に関する厳しいガイドライン

ポーターのファイブフォース：患者由来異種移植片/PDXモデル市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：患者由来異種移植片/PDXモデル市場における外部からの影響の把握

外部マクロ環境要因は、患者由来異種移植片/PDXモデル市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析患者由来異種移植片/PDXモデル市場における競合情勢の把握

患者由来異種移植片/PDXモデル市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス患者由来異種移植片/PDXモデル市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、患者由来異種移植片/PDXモデル市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨患者由来異種移植片/PDXモデル市場における成功への道筋を描く

患者由来異種移植片/PDXモデル市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療の需要の高まり
    • 腫瘍学と前臨床開発
    • 申請者が前臨床プログラムと文書を準備するための政府プログラムの資金とサービス
  • 抑制要因
    • パーソナライズされたPDXモデルの高コスト
  • 機会
    • 人間化されたPDXモデルの需要の高まり
    • 医薬品研究開発の成長
  • 課題
    • がん調査における動物の倫理的使用に関する厳格なガイドライン
• 市場セグメンテーション分析
  • タイプ：腫瘍学におけるマウスモデルの広範な使用による新規治療法の開発
  • 腫瘍の種類：婦人科がんを研究するための婦人科腫瘍モデルに重点を置く
  • 応用：基礎がん調査における患者由来異種移植（PDX）モデルの採用拡大
  • エンドユーザー：学術調査機関における患者由来異種移植の適用範囲の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 患者由来異種移植片/PDXモデル市場：タイプ別

• マウスモデル
• ラットモデル

第7章 患者由来異種移植片/PDXモデル市場腫瘍の種類別

• 消化管腫瘍モデル
• 婦人科腫瘍モデル
• 血液腫瘍モデル
• 呼吸器腫瘍モデル
• 泌尿器腫瘍モデル

第8章 患者由来異種移植片/PDXモデル市場：用途別

• がんの基礎調査
• バイオマーカー分析
• 前臨床医薬品開発

第9章 患者由来異種移植片/PDXモデル市場：エンドユーザー別

• 学術・調査機関
• 契約調査機関
• 製薬・バイオテクノロジー企業

第10章 南北アメリカの患者由来異種移植片/PDXモデル市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の患者由来異種移植片/PDXモデル市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの患者由来異種移植片/PDXモデル市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Invivo BiosystemsとBioreperiaが提携し、高度なPDXモデルでがん治療薬の試験を強化
  • KiyatecとXenostartは、Kiyatecの3DスフェロイドスクリーニングプラットフォームであるKiya-Predictを使用して相関的な体外有効性データを提供し、医薬品開発コストの削減を支援するための協力契約を正式に発表しました。
  • SoteriaとCertisがAIプラットフォームとマウス異種移植を使用して薬剤反応予測を生成するために提携
• 戦略分析と提言

企業一覧

• Abnova Corporation
• Altogen Labs
• Aragen Life Sciences Pvt. Ltd.
• BioDuro LLC
• BioReperia AB
• Champions Oncology, Inc.
• Creative Biolabs
• Crown Bioscience by JSR Corporation
• EPO Berlin-Buch GmbH
• GemPhamatech LLC
• Hera BioLabs Inc.
• Inotiv, Inc. by Bioanalytical Systems, Inc.
• InSphero AG
• LIDE Shanghai Biotech, Ltd.
• Oncodesign Services
• Pharmatest Services LLC by ValiRx Finland Oy
• TheraIndx Lifesciences Pvt. Ltd.
• Urosphere SAS
• WuXi AppTec Co., Ltd.
• XENTECH TECHNOLOGIES PRIVATE LIMITED

LIST OF FIGURES

• FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
• FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
• TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

The Patient-Derived Xenograft/PDX Model Market was valued at USD 326.36 million in 2023, expected to reach USD 365.24 million in 2024, and is projected to grow at a CAGR of 12.27%, to USD 734.07 million by 2030.

Patient-Derived Xenograft (PDX) models are indispensable tools in cancer research, representing a crucial bridge between in vitro studies and clinical applications. These models involve transplanting human tumor tissues into immunocompromised mice, thus maintaining the genetic heterogeneity of the patient's tumor. This fidelity makes PDX models invaluable for preclinical testing and accelerating personalized medicine initiatives. The necessity of PDX models lies in their ability to provide more accurate predictions of treatment efficacy, thereby aiding drug development and overcoming the limitations of traditional cell line models. They are primarily applied in oncology, supporting the screening of anti-cancer drugs and the development of biologics. The primary end-users include research institutions, pharmaceutical companies, and contract research organizations (CROs).

The market for PDX models is driven by the increasing prevalence of cancer, a robust pipeline of oncology drugs, and the growing emphasis on precision medicine. Technological advancements in gene editing and sequencing are also significantly propelling market growth. Emerging opportunities include the integration of artificial intelligence for data analysis and the development of 3D PDX models, which offer enhanced tumor microenvironment simulation. Companies can capitalize on these opportunities by investing in these areas to enhance model accuracy and predictability. However, challenges such as high costs of model development, ethical concerns regarding animal use, and limited accessibility for small biotechs may impede market growth.

To spur innovation, research should focus on optimizing the development process to reduce costs, increasing model diversity to cover rare cancer types, and advancing the co-clinical trial design to better correlate PDX findings with patient outcomes. Increasing collaborations between academic institutions and industry can also expedite innovation. The PDX model market is highly dynamic, characterized by continuous technological advances and a competitive landscape marked by strategic partnerships and acquisitions aimed at expanding service portfolios and geographical reach.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Patient-Derived Xenograft/PDX Model Market

The Patient-Derived Xenograft/PDX Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for personalized medicine
  • Oncology and preclinical development
  • Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
• Market Restraints
  • High cost of personalized PDX model
• Market Opportunities
  • Rising demand for humanized PDX Model
  • Growth in pharma R&D
• Market Challenges
  • Stringent guidelines regarding the ethical use of animals in cancer research

Porter's Five Forces: A Strategic Tool for Navigating the Patient-Derived Xenograft/PDX Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Patient-Derived Xenograft/PDX Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Patient-Derived Xenograft/PDX Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Patient-Derived Xenograft/PDX Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Patient-Derived Xenograft/PDX Model Market

A detailed market share analysis in the Patient-Derived Xenograft/PDX Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Patient-Derived Xenograft/PDX Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Patient-Derived Xenograft/PDX Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Patient-Derived Xenograft/PDX Model Market

A strategic analysis of the Patient-Derived Xenograft/PDX Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera BioLabs Inc., Inotiv, Inc. by Bioanalytical Systems, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Oncodesign Services, Pharmatest Services LLC by ValiRx Finland Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and XENTECH TECHNOLOGIES PRIVATE LIMITED.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Mice Models and Rat Models.
• Based on Tumor Type, market is studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Respiratory Tumor Models, and Urological Tumor Models.
• Based on Application, market is studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development.
• Based on End-User, market is studied across Academic & Research Institutions, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for personalized medicine
    • 5.1.1.2. Oncology and preclinical development
    • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of personalized PDX model
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising demand for humanized PDX Model
    • 5.1.3.2. Growth in pharma R&D
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
  • 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
  • 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
  • 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Patient-Derived Xenograft/PDX Model Market, by Type

• 6.1. Introduction
• 6.2. Mice Models
• 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

• 7.1. Introduction
• 7.2. Gastrointestinal Tumor Models
• 7.3. Gynecological Tumor Models
• 7.4. Hematological Tumor Models
• 7.5. Respiratory Tumor Models
• 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

• 8.1. Introduction
• 8.2. Basic Cancer Research
• 8.3. Biomarker Analysis
• 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Invivo Biosystems and Bioreperia Partner to Enhance Cancer Drug Testing with Advanced PDX Models
  • 13.3.2. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
  • 13.3.3. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abnova Corporation
• 2. Altogen Labs
• 3. Aragen Life Sciences Pvt. Ltd.
• 4. BioDuro LLC
• 5. BioReperia AB
• 6. Champions Oncology, Inc.
• 7. Creative Biolabs
• 8. Crown Bioscience by JSR Corporation
• 9. EPO Berlin-Buch GmbH
• 10. GemPhamatech LLC
• 11. Hera BioLabs Inc.
• 12. Inotiv, Inc. by Bioanalytical Systems, Inc.
• 13. InSphero AG
• 14. LIDE Shanghai Biotech, Ltd.
• 15. Oncodesign Services
• 16. Pharmatest Services LLC by ValiRx Finland Oy
• 17. TheraIndx Lifesciences Pvt. Ltd.
• 18. Urosphere SAS
• 19. WuXi AppTec Co., Ltd.
• 20. XENTECH TECHNOLOGIES PRIVATE LIMITED